T2D Flashcards
what is it
chronic metabolic condition characterised by insulin resistance and insufficient pancreatic insulin production resulting in hyperglycaemia
Commonly associated with
Obesity
Physical inactivity
Hypertension
Dyslipidaemia
Tendency to develop thrombosis - increased CV risk
Long term micro + macrovascular complications
Reduced QoL
Reduced life expectancy
Target HbA1c for T2D that is managed by diet and lifestyle alone, or when combined with a single antidiabetic drug that is not associated with hypoglycaemia (e.g. metformin)
48mmol/mol (6.5%)
Pt prescribed a single drug that IS associated with hypo (e.g. SU) should aim for HbA1c level of
53mmol/mol (7.0%)
what action to take if HbA1c levels poorly controlled despite treatment with a single drug & rise to 58mmol/mol (7.5%) or higher
intensify drug treatment alongside reinforcement of advice regarding diet, lifestyle and adherence
When 2 or more antidiabetics prescribed, target Hb1Ac level
53 mmol/mol (7.0%)
Consider relaxing target HbA1c level on a case-by-case basis - particular consideration for pt
Older or frail
Unlikely to achieve loner term risk reduction benefits
Tight blood glucose control not appropriate
High risk of consequences of hypoglycaemia
If pt reach a lower HbA1c level than their target, and are not experiencing hypo, encourage them to maintain it but be aware of other possible reasons for low level e.g.
deteriorating renal function or sudden weight loss
What is the HbA1c target generally recommended for T2D that is managed by diet and lifestyle alone, OR when combined with a single antidiabetic drug not associated with hypo?
48mmol/mol (6.5%)
What is the HbA1c target recommended for T2D that is being managed with a single drug that is associated with hypo (e.g. SU)?
53 mmol/mol (7.0%)
What is the target HbA1c level for patients taking 2 or more antidiabetic drugs?
53 mmol/mol (7.0%)
Consider rescue therapy with insulin or a SU for pt who become…
….somatically hyperglycaemic at any stage of treatment
Review treatment when BG control has been achieved
what treatment is recommended as 1st line for initial drug treatment for all pt and why
standard release metformin
Positive effect on weight loss (neutral to loss)
Reduced risk of hypo events
Long term CV benefits associated with use
dose of metformin
Increase dose gradually to minimise risk of GI SE
500mg OD for at least 1 week , take with breakfast, then 500mg BD for 1 week, take with breakfast and evening meal, then 500mg TDS (breakfast, lunch, evening), max 2g day
max dose of metformin
2g daily
metformin has to be taken with meals. as you titrate dose up, which meals do you take the tabs with
initially 500mg OD for a week - breakfast
then 500mg BD for a week - breakfast and dinner
then 500mg TDS - breakfast, lunch, dinner
MR metformin dose and titration - 2 options
initially 500mg OD, then increased up to 2g OD if needed, increase dose gradually, every 10-15 days, take dose with evening meal
alternatively increase to 1g BD, take with meals. only use this alternative dose if control is not achieved with OD dose regimen.
metformin dose for T2D reduction in risk or delay of onset.
use MR form. 500mg OD initially, then increase if necessary up to 2g OD, gradually increase every 10-15 days, take with evening meal
a patient has been commenced on metformin standard release tabs but experiences GI SE. what do. you do
offer MR metformin
1st line drug treatment for T2D in pt with chronic HF or established atherosclerotic CVD
- metformin + SGLT2i with proven CV benefit
- also consider SGTL2i in pt at high risk of developing CVD
- not erugliflozin as there is uncertainty around CV benefits with this
- start metformin first, then once tolerability to it is confirmed, start STGLT2i
If monotherapy with metformin (+ diet change) doesn’t control HbA1c level to below the agreed threshold, consider metformin +
DPP4 inhibitor (gliptins), or pioglitazone, or a SU
SGLT2 inhibitor may be considered in combination with metformin when SUs contraindicated or not tolerated, or if pt at significant risk of hypoglycaemia or its consequences
At any stage after starting initial treatment, offer an SGLT2 inhibitor with proven CF benefit to pt who
develop chronic heart failure or established atherosclerotic CV disease